THU0293 B-cell responses to type I interferon define disease activity in SLE and can be measured by cell surface tetherin (CD317)

• Published in: Annals of the rheumatic diseases Vol. 76; no. Suppl 2; p. 314
• Main Authors: El-Sherbiny, YM, Yusof, MY Md, Psarras, A, Hensor, E, Tooze, R, Doody, G, Wittmann, M, Emery, P, Vital, EM
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2017
• Subjects: Biomarkers; Cell surface; Diagnosis; Flow cytometry; Immunological memory; Interferon; Lymphocytes B; Lymphocytes T; Memory cells; Monoclonal antibodies; Monocytes; Musculoskeletal diseases; Rituximab

BackgroundSLE is a Type I interferon (IFN-I) mediated disease with autoreactive B cells. Whole blood interferon-stimulated gene (ISG) expression is used to measure IFN-I status but does not consistently correlate with clinical features and therapy response. ISG expression may be influenced by differ...